• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Deciphering molecular properties and docking studies of hepatitis C and non-hepatitis C antiviral inhibitors - A computational approach.

作者信息

Venkatesan Arthi, Febin Prabhu Dass J

机构信息

Department of Integrative Biology, School of Bio Sciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India.

Department of Integrative Biology, School of Bio Sciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India.

出版信息

Life Sci. 2017 Apr 1;174:8-14. doi: 10.1016/j.lfs.2017.02.014. Epub 2017 Mar 2.

DOI:10.1016/j.lfs.2017.02.014
PMID:28259653
Abstract

BACKGROUND

Hepatitis C is an infectious liver disease with high mortality rate which is caused by Hepatitis C virus. Several treatment methods have been applied to combat this deadly virus including interferons, vaccine and direct acting antivirals (DAAs). However, the later shows promising effects in HCV treatment with lower adverse effect. Specifically, the DAAs target the non-structural proteins (NS3 and NS5B).

PURPOSE

The objective of the present study is to hypothesize an alternative antiviral inhibitor for HCV from the available other antivirals.

METHODS

Computation of 2D molecular descriptors for the selected antiviral inhibitors followed by clustering the descriptor features. The closely clustered compounds were subjected to the interaction studies against the HCV target protein to validate the cluster result.

RESULTS AND DISCUSSION

The clustering result showed that indinavir (HIV inhibitor) and AT130 (HBV inhibitor) molecule are close to the HCV inhibitor. The indinavir complexed with NS3 protein shows -5.33kcal/mol and AT-130 complexed with NS5B protein possess the binding energy of -8.87kcal/mol. The docking interaction study indicated a better binding affinity than other viral inhibitors.

CONCLUSION

From the descriptor based feature similarity analysis and the interaction study, it can be concluded that indinavir and AT-130 could be a potential alternative agent for HCV treatment.

摘要

相似文献

1
Deciphering molecular properties and docking studies of hepatitis C and non-hepatitis C antiviral inhibitors - A computational approach.
Life Sci. 2017 Apr 1;174:8-14. doi: 10.1016/j.lfs.2017.02.014. Epub 2017 Mar 2.
2
Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels.基于笼状化合物的丙型肝炎病毒 p7 离子通道抑制剂的分子设计、合成与生物评价。
Eur J Med Chem. 2018 Oct 5;158:214-235. doi: 10.1016/j.ejmech.2018.08.009. Epub 2018 Aug 6.
3
Pharmacophore feature prediction and molecular docking approach to identify novel anti-HCV protease inhibitors.基于药效团特征预测和分子对接方法鉴定新型抗 HCV 蛋白酶抑制剂。
J Cell Biochem. 2018 Jan;119(1):960-966. doi: 10.1002/jcb.26262. Epub 2017 Aug 18.
4
Hepatitis C virus resistance to protease inhibitors.丙型肝炎病毒对蛋白酶抑制剂的耐药性。
J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1.
5
Rational Drug Discovery of HCV Helicase Inhibitor: Improved Docking Accuracy with Multiple Seeding in AutoDock Vina and In Situ Minimization.丙型肝炎病毒解旋酶抑制剂的合理药物发现:通过AutoDock Vina中的多种子对接和原位最小化提高对接准确性。
Curr Comput Aided Drug Des. 2017;13(2):160-169. doi: 10.2174/1573409912666161130122622.
6
Current race in the development of DAAs (direct-acting antivirals) against HCV.当前 HCV(丙型肝炎病毒)直接作用抗病毒药物(DAA)的研发进展。
Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13.
7
Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.直接作用抗病毒治疗成人丙型肝炎病毒感染:乙型肝炎病毒合并感染的再激活是一个进一步的挑战。
J Clin Virol. 2016 May;78:27-30. doi: 10.1016/j.jcv.2016.02.026. Epub 2016 Mar 3.
8
Hepatitis C treatment: an incipient therapeutic revolution.丙型肝炎治疗:初现的治疗革命。
Trends Mol Med. 2014 Jun;20(6):315-21. doi: 10.1016/j.molmed.2014.02.002. Epub 2014 Mar 11.
9
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).丙型肝炎病毒NS3/4A蛋白酶抑制剂ITMN-191(R7227)的临床前特征
Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41. doi: 10.1128/AAC.00699-08. Epub 2008 Sep 29.
10
Hepatitis C virus-specific directly acting antiviral drugs.丙型肝炎病毒特异性直接作用抗病毒药物。
Curr Top Microbiol Immunol. 2013;369:289-320. doi: 10.1007/978-3-642-27340-7_12.